Voyager Technologies Adds Two ISS Drug Discovery Missions With Exobiosphere

Key Points

• Voyager Technologies and Exobiosphere announced two additional drug-screening campaigns aboard the International Space Station.
• Exobiosphere’s Orbital High-Throughput Screening platform is scheduled for ISS installation in April 2027.
• The new campaigns are planned for June 2027 and the August–September 2027 period.
• Each campaign is designed to run thousands of experiments in microgravity alongside matching tests on Earth.
• Voyager Europe will manage mission integration, launch preparation, on-orbit coordination and sample return.

Voyager Technologies (NYSE: VOYG) and Exobiosphere are expanding their ISS research partnership with two additional campaigns for pharmaceutical and biotechnology customers. The missions will use Exobiosphere’s reusable drug-screening platform, giving separate research teams scheduled access to microgravity experiments without requiring a new system for each investigation.

Two ISS Research Campaigns Are Planned for 2027

Exobiosphere’s Orbital High-Throughput Screening, or OHTS, platform is scheduled to be installed on the ISS in April 2027. The first newly announced campaign is planned to launch on an ISS Program Commercial Resupply Services mission in June 2027, followed by a second campaign in the August–September 2027 timeframe.

The two customers represent different institutions and scientific objectives, according to the companies. Neither customer nor the specific research projects were identified in the announcement.

Reusable Platform Aims to Make Microgravity Research Repeatable

OHTS is a mid-deck-locker-class system designed for automated drug screening. Between campaigns, researchers can replace samples, test compounds and supplies, then adjust the platform’s setup for the next investigation.

Each campaign is designed to run thousands of experiments on standardized well plates. Matching experiments conducted on Earth will give researchers a comparison for interpreting the results from orbit. Exobiosphere said the resulting data could support drug-discovery programs, model development and new intellectual property; those are intended uses, not reported outcomes from the newly announced missions.

Voyager Will Manage Launch and ISS Operations

Under the companies’ existing master services agreement, Voyager Europe will handle program management, ISS integration and mission provisioning. Its responsibilities include safety and verification work, securing space on commercial resupply vehicles, coordinating operations aboard the station and arranging for samples to return to Earth.

Voyager’s affiliate Nanoracks LLC, doing business as Voyager Space Solutions, will handle final payload processing, NASA-required preflight preparations and console operations from its Houston-area facility.

What the Added Missions Mean

The two bookings show that separate organizations are planning research on the same orbital platform within a single year. Voyager and Exobiosphere see that repeat use as a step toward making ISS-based drug screening a service researchers can schedule. The campaigns remain planned missions, and the announcement does not report experimental findings or drug candidates resulting from them.